Second Division of Medical Oncology, Department of Medicine, 'Metaxa' Cancer Hospital, Pireaus, Greece.
Future Oncol. 2010 Nov;6(11):1803-9. doi: 10.2217/fon.10.138.
High-dose chemotherapy intensification and hematopoietic stem cell support remains a valuable treatment option for the rare patient with relapsed Wilms' tumor. We report a 22-year-old adult male with an initially diagnosed stage II Wilms' tumor, treated by nephrectomy followed by adjuvant chemotherapy. After 1 year, an intra-abdominal relapse was treated with salvage ifosfamide carboplatin etoposide chemotherapy followed by autologous hematopoietic stem cell mobilization. It was intended that he would receive two tandem cycles of high-dose chemotherapy; the first consisting of melphalan etoposide carboplatin; however, the patient did not return to receive the second cycle while in remission, but did return later with grossly relapsed disease. He was then treated with a novel preparative regimen incorporating high-dose topotecan (topotecan, melphalan and cyclophosphamide). This case confirms the feasibility of double high-dose chemotherapy with hematopoietic stem cell support in relapsed Wilms' tumor. A detailed discussion with an extensive review of the literature, regarding studies evaluating the role and indications of high-dose chemotherapy in Wilms' tumor is provided.
高剂量化疗强化和造血干细胞支持仍然是治疗罕见复发性肾母细胞瘤患者的有价值的治疗选择。我们报告了一名 22 岁的成年男性,最初诊断为 II 期肾母细胞瘤,接受了肾切除术和辅助化疗。1 年后,进行了挽救性伊立替康卡铂依托泊苷化疗和自体造血干细胞动员,以治疗腹内复发。本打算让他接受两次高剂量化疗的串联周期;第一个周期包括美法仑依托泊苷卡铂;然而,患者在缓解期没有返回接受第二个周期,但后来疾病明显复发后返回。然后,他接受了一种新的包含高剂量拓扑替康的预处理方案(拓扑替康、美法仑和环磷酰胺)。该病例证实了在复发性肾母细胞瘤中进行造血干细胞支持的双高剂量化疗的可行性。提供了详细的讨论和广泛的文献回顾,涉及评估高剂量化疗在肾母细胞瘤中的作用和适应证的研究。